Matti Jauhiainen (Finland)

Minerva Foundation Institute for Medical Research Cardiometabolic diseases
Dr Jauhiainen is currently working as a senior scientist at Minerva Foundation Institute for Medical Research, Helsinki. He received his PhD in the University of Kuopio in 1984 and during the same year he received certification in clinical chemistry. He worked as a post-doctoral fellow during 1984-1988 at Dalhousie University, Halifax, Canada and since 1988 he affiliated to National Institute of Health and worked there for 28 yrs. He was appointed in 1991 adj.professor at the University of Helsinki. Since 2001 he has regularly given lectures to medical, dentistry and nutrition science students at the University of Helsinki. He is a member as well as has served a committee member in several professional societies such as Scandinavian Society for Atherosclerosis Research, European Atherosclerosis Society, European Lipoprotein Club and is a past president of the Finnish Atherosclerosis Society. He was also a Finnish management committee member in EU-COST action on HDL. He has supervised several PhD theses and has acted as an opponent for PhD/MD theses in Finland and abroad. He has published several peer-reviewed reports and reviews. His major research areas include topics such as lipids/lipoproteins, especially structure and function of HDL, mechanisms of cardiometabolic diseases and the role of ANGPTL - proteins in lipid and glucose metabolism.

Author Of 3 Presentations

Introduction (ID 1499)

Session Type
Lipoproteins and Metabolism
Session Time
16:00 - 17:30
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
16:00 - 16:03

Conclusion (ID 1500)

Session Type
Lipoproteins and Metabolism
Session Time
16:00 - 17:30
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
17:13 - 17:16

O062 - Children with familial hypercholesterolemia display changes in LDL and HDL function: a cross-sectional study (ID 1406)

Session Type
Late Breaking Sessions
Session Time
10:00 - 11:15
Date
Wed, 02.06.2021
Room
Hall A (Live Q&A)
Lecture Time
10:28 - 10:35

Abstract

Background and Aims

The functional status of lipoprotein particles contributes to atherogenesis. The tendency of plasma LDL particles to aggregate and the ability of HDL particles to induce and mediate reverse cholesterol transport associate with high and low risk for cardiovascular disease in adult patients, respectively. However, it is unknown whether children with familial hypercholesterolemia (FH) display lipoprotein function alterations.

We hypothesized that FH children had disrupted lipoprotein function.

Methods

We analyzed LDL aggregation susceptibility and HDL-apoA-I exchange to apoA-I ratio (HAE/apoA-I ratio), and activity of four proteins that regulate lipoprotein metabolism (CETP, LCAT, PLTP and PON1) in plasma samples derived from children with FH (n = 47) and from healthy children (n = 56). Potential biological mechanisms behind any variation in lipoprotein functionalities were explored using an NMR-based metabolomics profiling approach.

Results

LDL aggregation was higher and HAE/apoA-I ratio was lower in FH children than in healthy children. LDL aggregation associated positively with LDL-C and negatively with triglycerides, and HAE/apoA-I ratio associated negatively with LDL-C. Generally, the metabolomic profile for LDL aggregation was a mirror image of that for HAE/apoA-I ratio.

Conclusions

FH children displayed increased atherogenicity of LDL and disrupted HDL function. These newly observed functional alterations in LDL and HDL may help explain the risk for atherosclerotic cardiovascular disease in FH children.

Hide

Presenter of 2 Presentations

Conclusion (ID 1500)

Session Type
Lipoproteins and Metabolism
Session Time
16:00 - 17:30
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
17:13 - 17:16

Introduction (ID 1499)

Session Type
Lipoproteins and Metabolism
Session Time
16:00 - 17:30
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
16:00 - 16:03